Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation (PATHFINDER)
Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER
This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Amber St Martin
- Phone Number: 612-380-5637
- Email: rs.pathfinder@medtronic.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham (UAB) Hospital
-
Principal Investigator:
- Mustafa Ahmed, MD
-
Contact:
- Kathy Phillips
- Phone Number: 205-975-1888
- Email: kcphillips@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Abrazo Arizona Heart Hospital
-
Principal Investigator:
- Timothy Byrne, MD
-
Contact:
- Jesica Byrne
- Phone Number: 602-952-0002
- Email: jessica.byrne@abrazohealth.com
-
-
California
-
Thousand Oaks, California, United States, 91360
- Recruiting
- Los Robles Hospital & Medical Center
-
Principal Investigator:
- Saibal Kar, MD
-
Contact:
- Jason Yashar
- Phone Number: 805-796-5881
- Email: jason.yashar@hcahealthcare.com
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale New Haven Hospital
-
Principal Investigator:
- Amit Vora, MD
-
Contact:
- Scott Ardito
- Phone Number: 203-737-3570
- Email: scott.ardito@yale.edu
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Recruiting
- Emory University Hospital Midtown
-
Principal Investigator:
- Adam Greenbaum, MD
-
Contact:
- Elizabeth Charles
- Phone Number: 404-686-1249
- Email: elizabeth.z.charles@emory.edu
-
Contact:
- Maria Kaner
- Phone Number: 404-313-6971
- Email: maria.kaner@emory.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern Memorial Hospital
-
Principal Investigator:
- Anita Asgar, MD
-
Contact:
- Maggie McNamara
- Phone Number: 312-926-0846
- Email: margaret.mcnamara@nm.org
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Recruiting
- Abbott Northwestern Hospital
-
Principal Investigator:
- Konstantinos Voudris, MD
-
Contact:
- Jennifer Nguyen
- Phone Number: 612-863-9291
- Email: jennifer.nguyen@allina.com
-
-
New York
-
Buffalo, New York, United States, 14203
- Recruiting
- Buffalo General Medical Center
-
Principal Investigator:
- Vijay Iyer, MD
-
Contact:
- Cassandra Davern
- Phone Number: 716-881-8299
- Email: cadavern@buffalo.edu
-
Manhasset, New York, United States, 11030
- Recruiting
- Northwell Health North Shore University Hospital
-
Principal Investigator:
- Bruce Rutkin, MD
-
Contact:
- Samantha Annunziato
- Phone Number: 516-562-2653
- Email: sannunziato@northwell.edu
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Medical Center
-
Principal Investigator:
- Mathew Williams, MD
-
Contact:
- Sara Hanahan
- Phone Number: 929-989-5764
- Email: sara.hanahan@nyulangone.org
-
New York, New York, United States, 10467
- Recruiting
- Montefiore Medical Center
-
Principal Investigator:
- Azeem Latib, MD
-
Contact:
- Angela Yang
- Phone Number: 718-920-6431
- Email: anyang@montefiore.org
-
Contact:
- Tammy Rodriguez Guzman
- Phone Number: 718-920-4595
- Email: tamrodrigu@montefiore.org
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- The Christ Hospital
-
Principal Investigator:
- Puvi Seshiah, MD
-
Contact:
- Jamie Elkins
- Phone Number: 513-585-1640
- Email: jamie.elkins@thechristhospital.com
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Foundation
-
Principal Investigator:
- Amar Krishnaswamy, MD
-
Contact:
- Toni Zimmerman
- Phone Number: 216-444-6452
- Email: zimmert5@ccf.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years at the time of consent.
- Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT).
- Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR.
Exclusion Criteria:
- Any tricuspid device currently in place.
- Anatomic contraindications.
- Need for emergent or urgent surgery.
- Left ventricular ejection fraction <25%.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Medtronic Intrepid™ TTVR
Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation. |
Transcatheter Tricuspid Valve Replacement |
|
Active Comparator: Edwards EVOQUE TTVR
Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation. |
Transcatheter Tricuspid Valve Replacement |
|
Experimental: Single Arm Registry
Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization. |
Transcatheter Tricuspid Valve Replacement |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of Major Adverse Events (MAE)
Time Frame: 30-days post-procedure
|
30-days post-procedure
|
|
Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention
Time Frame: 1-year post-procedure
|
1-year post-procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause mortality
Time Frame: 12 months post-procedure
|
12 months post-procedure
|
|
|
Heart failure hospitalization
Time Frame: 12 months post-procedure
|
12 months post-procedure
|
|
|
New onset conduction disturbance (NOCD)
Time Frame: 30 days post-procedure
|
30 days post-procedure
|
|
|
Total procedure time
Time Frame: Procedure
|
Procedure
|
|
|
Right ventricle (RV) dysfunction
Time Frame: 12 months post-procedure
|
12 months post-procedure
|
|
|
Tricuspid regurgitation (TR) grade reduction
Time Frame: 6 months post-procedure
|
Total number of patients with at least one grade TR reduction |
6 months post-procedure
|
|
Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline
Time Frame: 6 months post-procedure
|
KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life |
6 months post-procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Azeem Latib, MD, Montefiore Medical Center
- Principal Investigator: Vinayak N. Bapat, MD, Minneapolis Heart Institute
- Principal Investigator: Anita Asgar, MD, Northwestern Medicine Bluhm Cardiovascular Institute
- Principal Investigator: Nicolas Dumonteil, MD, Clinique Pasteur Groupe CardioVasculaire Interventionnel
- Principal Investigator: Firas Zahr, MD, Knight Cardiovascular Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MDT23032TMV006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.